We are constantly exploring opportunities to initiate drug development programs that address areas of defined unmet need—particularly for children with cancer.
In addition to our efforts to maximize the potential impact of DAY101 (tovorafenib), we are in-licensing new compounds that fit our all ages strategy and capabilities.
For example, we’re exploring combinations of tovorafenib with other MAPK pathway-targeted agents (such as pimasertib) and other targeted therapies. Our goal is to better address underserved diseases, extend the duration of therapeutic benefit and achieve long-term durable remission for patients of every age.
Utilizing our broad experience and network of industry, clinical and scientific experts, we’re constantly evaluating additional high-impact programs to further enhance our pipeline for cancer and other life-threatening diseases.
If you have a great development idea, we’d like to hear from you. Contact us at [email protected].